1980 Volume 54 Issue 5 Pages 256-263
A field experiment was carried out with influenza vaccines prepared from various strains. Its purposes were to examine each vaccine for effect on the living body to increase in titer of hemagglutination-inhibiting (HI) antibody and neuraminidase-inhibiting antibody and for effect of inoculation.
1. Inoculation was done with three vaccines, vaccine prepared from the A/Kumamoto/22/76 (H3N2) strain and A 1 (OH) 2-added adjuvant vaccines from the A/Kumamoto/22/76 (H3N2) strain (800 and 400 CCA/ml, respectively). Neuraminidase-inhibiting antibody in the serum was estimated before and one month after inoculation.
No rise in antibody titer was seen in those inoculated with the first vaccine. A two-to fivefold increase in antibody titer was noticed in three of nine persons inoculated with the adjuvant vaccine (800 CCA/ml) one month after inoculation. An increase 40-70 times on the average was observed in those inoculated with the adjuvant vaccine (400 CCA/ml) one month after inoculation.
Some persons were selected from among those inoculated with these vaccines, except the adjuvant vaccine (400 CCA/ml). In each of them the effect of vaccination was compared between HI and neuraminidase-inhibiting antibodies. The same degree of increase in titer was not always seen in both antibodies.
2. Ability to produce antibody was compared between vaccine prepared from highly multiplicableinfluenza virus [A/Kumamoto/22/76-A/PR/8/34 (H3N2) strain] and vaccine from the A/Kumamoto/22/76 (H3N2) strain.
When the vaccine strain was used as antigen, a more than fourfold increase in HI antibody titer was found in 60% of those inoculated with the latter vaccine one month after inoculation. It was found in 73% of the same inoculated persons at the same time when the former strain was used as antigen. When the vaccine strain was used as antigen, a more than fourfold increase in HI antibody titer was noticed in 76% of those inoculated with the former vaccine one month after inoculation. It was noticed in 64% of the same inoculated persons at the same time when the A/Kumamoto/22/76 strain was used as antigen. There was no large difference in ability to produce antibody in human beings between vaccine prepared from the original strain and recombinant virus vaccine.
